Pokrovsky S N, Sussekov A V, Afanasieva O I, Adamova I Y, Lyakishev A A, Kukharchuk V V
Institute of Experimental Cardiology, Cardiology Research Center, Moscow, Russia.
Chem Phys Lipids. 1994 Jan;67-68:323-30. doi: 10.1016/0009-3084(94)90153-8.
The extracorporeal procedure for the specific removal of lipoprotein (a) (Lp(a)) from human plasma--Lp(a) apheresis--was applied to the treatment of three patients with coronary artery disease documented by angiography. Their initial lipid levels were as follows: total cholesterol, 210-230 mg/dl; low-density lipoprotein (LDL) cholesterol, 140-160 mg/dl; Lp(a), 90-120 mg/dl. The patients underwent a total of 168 procedures without significant side effects. Lp(a) apheresis reduced the Lp(a) level by removing up to 88% of Lp(a). Other plasma compounds, including LDL and plasminogen, remained practically unchanged. Lp(a) apheresis appears to be a unique, effective and specific method for lowering the Lp(a) level. Additional trials are needed to evaluate the clinical effect of this treatment.
用于从人血浆中特异性去除脂蛋白(a) [Lp(a)] 的体外程序——Lp(a) 单采术，被应用于治疗3例经血管造影证实患有冠状动脉疾病的患者。他们最初的血脂水平如下：总胆固醇，210 - 230 mg/dl；低密度脂蛋白（LDL）胆固醇，140 - 160 mg/dl；Lp(a)，90 - 120 mg/dl。这些患者总共接受了168次程序，没有明显的副作用。Lp(a) 单采术通过去除高达88%的Lp(a) 降低了Lp(a) 水平。包括LDL和纤溶酶原在内的其他血浆成分实际上保持不变。Lp(a) 单采术似乎是一种降低Lp(a) 水平的独特、有效且特异性的方法。需要进行更多试验来评估这种治疗的临床效果。
